Baguley Campbell, Brownlow Amanda, Yeung Kaye, Pratt Ellie, Sacks Raymond, Harvey Richard
Dept of Otolaryngology, Wellington Hospital, Wellington, New Zealand; Applied Medical Research Centre, St. Vincent's Hospital, Sydney, Australia.
Int Forum Allergy Rhinol. 2014 Jul;4(7):525-32. doi: 10.1002/alr.21315. Epub 2014 Mar 7.
Many chronic rhinosinusitis (CRS) treatment regimes revolve around "one-off" maximal medical therapy (MMT) protocols, and although many patients initially respond, long-term control is unpredictable. The value of imaging, endoscopy, and patient progress after MMT for CRS is assessed.
Symptomatic CRS patients with computed tomography (CT)-confirmed disease were recruited at a tertiary rhinology clinic. All patients received at least a 3-week oral prednisone course as part of their MMT. Pretreatment and posttreatment nasal symptoms scores (NSS), quality of life (22-item SinoNasal Outcomes Test [SNOT-22]), and CT (Lund-Mackay [LM]) scores were recorded along with post-MMT endoscopy status.
A total of 86 patients (38% female, age 46 ± 13 years) met inclusion criteria. Pre-MMT and post-MMT LM scores were 10.9 ± 5.3 and 8.3 ± 5.5 (change 2.6 ± 3.8, p < 0.001). Median follow-up after their initial post-MMT assessment was 6.3 (interquartile range [IQR] 17) months. At initial post-MMT review, 43 (50%) were symptomatic with persistent radiologic disease ("symptomatic CRS"), 12 (14%) were asymptomatic with no radiologic disease ("resolved CRS"), 21 (24%) were asymptomatic with persistent radiologic disease ("asymptomatic CRS"), and 10 (12%) were symptomatic with no radiologic disease ("alternate diagnosis"). Pre-MMT NSS and SNOT-22 were similar among groups. The "asymptomatic CRS" group had the highest age (52 ± 11 years, p = 0.07). The "alternate diagnosis" group had the lowest initial LM scores (5.2 ± 2.9, p = 0.001). Of the "asymptomatic CRS" patients, 43% relapsed between 3 and 23 months (median 6; IQR 4.4 months) post-MMT and 29% eventually underwent surgery.
Although MMT for CRS achieved symptomatic relief in 38% patients, objective evidence of disease was associated with clinical relapse. The concepts of "response" to medical therapy and the need to "control" long-term inflammatory burden need to be balanced.
许多慢性鼻 - 鼻窦炎(CRS)治疗方案围绕“一次性”最大程度药物治疗(MMT)方案展开,尽管许多患者最初有反应,但长期控制效果难以预测。本研究评估了MMT治疗CRS后影像学、内镜检查及患者病情进展的价值。
在一家三级鼻科诊所招募经计算机断层扫描(CT)确诊的有症状CRS患者。所有患者作为MMT的一部分接受至少为期3周的口服泼尼松疗程。记录治疗前和治疗后的鼻症状评分(NSS)、生活质量(22项鼻鼻窦结局测试[SNOT - 22])、CT(Lund - Mackay [LM])评分以及MMT后的内镜检查情况。
共有86例患者(女性占38%,年龄46±13岁)符合纳入标准。MMT前和MMT后的LM评分分别为10.9±5.3和8.3±5.5(变化2.6±3.8,p<0.001)。首次MMT后评估的中位随访时间为6.3(四分位间距[IQR]17)个月。在首次MMT后复查时,43例(50%)有症状且存在持续性影像学病变(“有症状CRS”),12例(14%)无症状且无影像学病变(“已缓解CRS”),21例(24%)无症状但存在持续性影像学病变(“无症状CRS”),10例(12%)有症状但无影像学病变(“其他诊断”)。各组治疗前NSS和SNOT - 22相似。“无症状CRS”组年龄最大(52±11岁,p = 0.07)。“其他诊断”组初始LM评分最低(5.2±2.9,p = 0.0)。在“无症状CRS”患者中,43%在MMT后3至23个月(中位时间6个月;IQR 4.4个月)复发,29%最终接受了手术。
尽管CRS的MMT使38%的患者症状得到缓解,但疾病的客观证据与临床复发相关。需要平衡药物治疗“反应”的概念和“控制”长期炎症负担的必要性。